GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexon Inc (NAS:ANNX) » Definitions » Net-Net Working Capital

ANNX (Annexon) Net-Net Working Capital : $1.86 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Annexon Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Annexon's Net-Net Working Capital for the quarter that ended in Mar. 2025 was $1.86.

The industry rank for Annexon's Net-Net Working Capital or its related term are showing as below:

ANNX's Price-to-Net-Net-Working-Capital is ranked better than
82.8% of 878 companies
in the Biotechnology industry
Industry Median: 4.025 vs ANNX: 1.26

Annexon Net-Net Working Capital Historical Data

The historical data trend for Annexon's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexon Net-Net Working Capital Chart

Annexon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net-Net Working Capital
Get a 7-Day Free Trial 8.90 4.86 3.96 2.71 2.33

Annexon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 3.07 2.77 2.33 1.86

Competitive Comparison of Annexon's Net-Net Working Capital

For the Biotechnology subindustry, Annexon's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annexon's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexon's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Annexon's Price-to-Net-Net-Working-Capital falls into.


;
;

Annexon Net-Net Working Capital Calculation

Annexon's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net-Net Working Capital(A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(312.017+0.75 * 0+0.5 * 0-56.966
-0-0)/109.382
=2.33

Annexon's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2025 is calculated as

Net-Net Working Capital(Q: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(263.696+0.75 * 0+0.5 * 0-59.239
-0-0)/109.714
=1.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Annexon  (NAS:ANNX) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Annexon Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Annexon's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Annexon Business Description

Traded in Other Exchanges
N/A
Address
1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Executives
Dean Richard Artis officer: EVP & Chief Scientific Officer C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005
Jennifer Lew officer: EVP & Chief Financial Officer 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Ted Yednock officer: EVP & Chief Innovation Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Overdorf officer: EVP & Chief Business Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Douglas Love director, officer: President & CEO C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William H. Carson director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016
Muneer A Satter director C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Bain Capital Life Sciences Fund, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Larry Mattheakis officer: Chief Scientific Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Sanjay Keswani officer: EVP & Chief Medical Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Clarus Lifesciences Iii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017